QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mizuho-maintains-outperform-on-cencora-raises-price-target-to-334

Mizuho analyst Steven Valiquette maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $316 to $334.

 cencoras-intrinsiq-expands-oncology-biomarker-data-and-therapeutic-insights-to-advance-precision-medicine-and-support-biopharmaceutical-innovation

Biomarker data, enhanced therapeutic data and insights will enable biopharmaceutical innovation and physician support through i...

Core News & Articles

https://www.youtube.com/watch?v=2KW1mVChh-c&feature=youtu.be

 wells-fargo-maintains-overweight-on-cencora-raises-price-target-to-354

Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $337 to $...

 wall-street-recovers-apple-rallies-6-on-100-billion-gov-manufacturing-investment-whats-moving-markets-wednesday

U.S. stocks rebounded sharply on Wednesday, fully erasing last Friday's losses, as upbeat corporate earnings and renewed in...

 cencora-says-famed-glp-1-class-products-drive-growth-boosts-profit-outlook

Cencora reports Q3 sales of $80.66 billion and EPS of $4.00, both above estimates, driven by GLP-1 and specialty drug demand in...

 cencora-raises-fy2025-adj-eps-guidance-from-1570-1595-to-1585-1600-vs-1581-est-updates-fy2025-sales-guidance-from-317368b-323245b-to-approximately-320306b-vs-321637b-est

Fiscal Year 2025 ExpectationsCencora is now updating its fiscal year 2025 financial guidance primarily to reflect stronger earn...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION